Gilman Hill Asset Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Gilman Hill Asset Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-650	Closed	-$290K	–	246
2026 Q1	$290K	Buy	+650	New	+$303K	0.04%	188
2022 Q1	–	Sell	-1,025	Closed	-$225K	–	224
2021 Q4	$225K	Buy	+1,025	New	+$199K	0.05%	200
2020 Q3	–	Sell	-700	Closed	-$203K	–	166
2020 Q2	$203K	Buy	+700	New	+$190K	0.08%	152

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Gilman Hill Asset Management's VRTX Position: Q2 2026 in Review

Gilman Hill Asset Management sold out of Vertex Pharmaceuticals (VRTX) in Q2 2026, closing a stake of 650 shares — an estimated $290K sold.

Gilman Hill Asset Management first reported a position in VRTX in Q2 2020 and held it in 3 quarters. The position peaked at $290K in Q1 2026. 1,762 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Gilman Hill Asset Management reported no remaining Vertex Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Gilman Hill Asset Management sold 650 Vertex Pharmaceuticals shares in Q2 2026, an estimated $290K.
Gilman Hill Asset Management first reported a position in Vertex Pharmaceuticals in Q2 2020 and held it in 3 quarters.
Gilman Hill Asset Management's Vertex Pharmaceuticals position peaked at $290K in Q1 2026.
1,762 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Gilman Hill Asset Management's 13F filing for Q2 2026, filed 9 Jul 2026.